Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-cell therapy in combination with vemurafenib for BRAF mutated metastatic melanoma
2014-001419-38Phase 2Completed
- Sponsor
- Center for Cancer Immune Therapy
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in melanoma, sponsored by Center for Cancer Immune Therapy. Primary endpoint: Toxicity (CTCAE v4.0). Started Apr 2014; status: completed.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-001419-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001419-38.